INTRODUCTION {#s1}
============

Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide and the third most common cause of cancer mortality \[[@R1], [@R3]\]. In Asian countries, hepatitis B virus (HBV) infection has been identified as an important etiological factor in hepatocarcinogenesis. Patients with HBV-related HCC therefore require pre- or postoperative antiviral treatment, which can induce remission of active hepatitis, help maintain hepatic function, prevent HCC recurrence and increase the likelihood of successful treatment if the disease does recur \[[@R4]\].

Such postoperative antiviral therapy may not be enough. Numerous studies have shown that conformal radiotherapy \[[@R5]--[@R6]\], systemic chemotherapy \[[@R7]--[@R8]\], radiofrequency ablation \[[@R9]\] and transcatheter arterial chemoembolization (TACE) \[[@R10]--[@R11]\] can lead to HBV reactivation and hepatic dysfunction during treatment. Hepatectomy of patients with HBV-related HCC who are positive for HBV DNA in serum can lead to HBV reactivation during the perioperative period, and patients positive for HBV DNA or HBV surface antigen (HBsAg) may be at particularly high risk of reactivation \[[@R7], [@R9]\]. HBV reactivation can degrade liver function \[[@R12]\], aggravateliver cirrhosis \[[@R13]\], increase the risk of HBV-related HCC recurrence \[[@R14]\], and increase the incidence and severity of potentially life-threatening complications \[[@R15]\]. For these reasons, official guidelines \[[@R16]--[@R19]\] recommend simultaneous comprehensive anti-tumor treatment and antiviral treatment for HCC patients positive for HBV DNA.

It is unclear whether antiviral therapy during the perioperative period can also benefit patients who have HBV-related HCC but who are *negative* for HBV DNA. The present study evaluated the incidence of post-hepatectomy HBV reactivation in such patients and explored the risk factors of reactivation. The influence of HBV reactivation on liver function recovery was also analyzed.

RESULTS {#s2}
=======

Study population characteristics {#s2_1}
--------------------------------

During the enrollment period, 1,684 potentially eligible patients were admitted for initial hepatectomy at our hospital between July 2012 and June 2016. Of these, 1489 were excluded because they were negative for serum HBsAg (*n* = 32), positive for HBV DNA (*n* = 1455) or positive for antibodies against hepatitis C virus (*n* = 2). A total of 195 patients who had HBV-related HCC and who were positive for serum HBsAg and negative for HBV DNA prior to hepatectomy were enrolled. After enrollment, 17 patients were excluded because they received TACE or other antitumor therapy before hepatectomy (*n* = 8), they had previously received antiviral therapy within one year of study enrollment (*n* = 7), or they had another cancer (*n* = 1) or autoimmune disease (*n* = 1). Another 4 patients were excluded when postoperative histopathology showed them to have intrahepatic cholangiocarcinoma. In the end, 66 patients were included in the antiviral group and 108 in the non-antiviral group (Figure [1](#F1){ref-type="fig"}).

![Patient enrollment and assessment](oncotarget-08-15047-g001){#F1}

The proportion of patients receiving minor hepatectomy was significantly higher in the antiviral group (*P* = 0.041), who also had a significantly lower mean albumin level than the non-antiviral group (*P* = 0.032). The two groups were similar across all other variables analyzed (all *P* \> 0.05; Table [1](#T1){ref-type="table"}).

###### Baseline characteristics of included patients

  Variable                                               Antiviral group(*n* = 66)   Non-antiviral group(*n* = 108)   *P*
  ------------------------------------------------------ --------------------------- -------------------------------- -------
  Sex (M/F)                                              58/8                        92/16                            0.617
  Age (yr)                                               49.97 ± 9.71                49.67 ± 12.22                    0.904
  BCLC stage (A/B/C)                                     42/12/12                    60/20/28                         0.466
  Tumor number (\< 3/≥ 3)                                56/10                       98/10                            0.237
  Tumor size (\> 5/≤ 5 cm)                               34/32                       62/46                            0.448
  Preoperative tumor rupture (yes/no)                    4/62                        6/102                            1.000
  Blood loss (mL)                                        448.42 ± 303.73             459.26 ± 219.74                  0.848
  Blood transfusion (yes/no)                             2/64                        8/100                            0.322
  Operative time (min)                                   202.58 ± 69.41              195.50 ± 53.65                   0.595
  Tumor capsule (complete/absent + incomplete)           44/22                       64/44                            0.329
  Anatomical hepatectomy (yes/no)                        12/54                       34/74                            0.054
  Inflow blood occlusion time (min)                      28.03 ± 25.40               24.98 ± 38.88                    0.690
  Liver cirrhosis (present/absent)                       54/12                       87/21                            0.837
  Alpha fetoprotein ≥ 400 ng/mL                          32                          50                               0.779
  Prothrombin time (s)                                   12.82 ± 1.29                12.77 ± 1.41                     0.857
  Total bilirubin (μmol/L)                               10.50 ± 3.85                20.17 ± 5.37                     0.303
  Albumin (g/L)                                          40.24 ± 5.19                42.57 ± 4.61                     0.032
  Alanine aminotransferase (IU/L)                        20.97 ± 15.08               22.39 ± 17.61                    0.617
  Ascites (present/absent)                               2/64                        2/106                            0.635
  Types of hepatectomy (major/minor)                     4/62                        18/90                            0.041
  Hepatitis B virus Pre-S1 antigen (positive/negative)   46/20                       60/48                            0.064

BCLC, Barcelona Clinic Liver Cancer.

HBV reactivation {#s2_2}
----------------

By 1-month follow-up, HBV reactivation had occurred in a significantly larger proportion of patients in the non-antiviral group \[30/108, (27.8%)\] than in the antiviral group \[2/64 (3.0%), *P* \< 0.001\]. Most reactivation events occurred soon after surgery: 8 patients experienced initial reactivation on postoperative day 1, 16 patients on day 3 (including the two patients in the antiviral group), 5 patients on day 5, 2 patients on day 7, and 1 patient on day 9. Patients who experienced reactivation were considered for antiviral therapy (Table [2](#T2){ref-type="table"}).

###### HBV DNA levels in patients in the antiviral and non-antiviral groups who experienced HBV reactivation within 1 month of hepatectomy

  -------------------------------------------------------------------------------------
  Day\                                    D0   D1     D3     D5     D7     D9    D30
  Patient                                                                        
  --------------------------------------- ---- ------ ------ ------ ------ ----- ------
  1                                       ≥    872    826    893    840    795   780

  2                                       ≥    500    771    795    780    764   750

  3                                       ≥    1012   1025   1109   1018   997   1007

  4                                       ≥    695    708    713    677    701   700

  5                                       ≥    598    631    621    587    600   624

  6                                       ≥    725    713    751    720    704   700

  7                                       ≥    818    843    819    800    792   805

  8                                       ≥    796    826    819    804    788   827

  9                                       ≥    ≥      912    897    901    850   829

  10                                      ≥    ≥      738    725    771    698   708

  11                                      ≥    ≥      852    842    880    799   813

  12                                      ≥    ≥      924    854    869    941   850

  13                                      ≥    ≥      713    402    750    692   700

  14                                      ≥    ≥      816    800    806    794   750

  15                                      ≥    ≥      903    885    897    904   916

  16                                      ≥    ≥      759    746    782    729   741

  17                                      ≥    ≥      685    653    674    627   608

  18                                      ≥    ≥      599    586    607    581   620

  19                                      ≥    ≥      619    627    641    608   574

  20                                      ≥    ≥      598    571    588    559   607

  21                                      ≥    ≥      667    695    684    673   650

  22                                      ≥    ≥      652    677    692    628   672

  23                                      ≥    ≥      954    928    973    900   929

  24                                      ≥    ≥      856    849    872    827   867

  25                                      ≥    ≥      ≥      873    859    894   807

  26                                      ≥    ≥      ≥      691    685    726   708

  27                                      ≥    ≥      ≥      655    639    675   649

  28                                      ≥    ≥      ≥      863    855    849   895

  29                                      ≥    ≥      ≥      529    537    542   518

  30                                      ≥    ≥      ≥      ≥      639    622   640

  31[\*](#tfn_001){ref-type="table-fn"}   ≥    ≥      ≥      ≥      593    607   612

  32[\*](#tfn_001){ref-type="table-fn"}   ≥    ≥      ≥      ≥      ≥      526   538
  -------------------------------------------------------------------------------------

Patients in the antiviral group who experienced HBV reactivation. D0, preoperative HBV DNA level (baseline); D1, D3, D5, D7, D9, D30 etc., postoperative HBV DNA levels; ≥, HBV DNA level \< 500 IU/ml.

Univariate analysis identified the following risk factors of perioperative HBV reactivation (all *P* \< 0.05; Table [3](#T3){ref-type="table"}): cirrhosis, low serum albumin, minor hepatectomy and absence of antiviral therapy. Multivariate analysis identified only two risk factors (*P* \< 0.05; Table [4](#T4){ref-type="table"}): minor hepatectomy and absence of antiviral therapy.

###### Univariate analysis to identify factors related to perioperative HBV reactivation

  Variable                                               HBV reactivation (*n* = 32)   No HBV reactivation (*n* = 142)   *P*
  ------------------------------------------------------ ----------------------------- --------------------------------- ----------
  Sex (M/F)                                              28/4                          122/20                            1.000
  Age (yr)                                               50.25 ± 11.01                 49.68 ± 11.41                     0.855
  BCLC-stage (A/B/C)                                     16/10/6                       86/22/34                          0.115
  Tumor numbers (\< 3/≥ 3)                               28/4                          126/16                            0.766
  Tumor size (\> 5/≤ 5cm)                                16/16                         80/62                             0.515
  Tumor size(cm)                                         5.83 ± 2.60                   6.94 ± 4.08                       0.299
  Preoperative tumor rupture (yes/no)                    2/30                          8/134                             1.000
  Blood loss (mL)                                        323.13 ± 238.38               362.37 ± 257.49                   0.578
  Blood transfusion (yes/no)                             3/29                          7/135                             0.394
  Operative time(min)                                    194.38±53.26                  199.04±61.52                      0.780
  Tumor capsule (complete/ absent+ incomplete)           20/12                         88/54                             0.956
  Anatomical hepatectomy (yes/no)                        8/24                          38/104                            0.838
  Inflow blood occlusion time (min)                      21.00 ± 14.72                 25.04 ± 23.61                     0.514
  Liver cirrhosis (present/absent)                       30/2                          111/31                            0.042
  Alpha fetoprotein ≥ 400 ng/mL                          12                            70                                0.227
  Prothrombin time (s)                                   12.95 ± 1.95                  12.75 ± 1.20                      0.599
  Total bilirubin (μmol/L)                               13.98 ± 6.43                  17.08 ± 46.70                     0.792
  Albumin (g/L)                                          44.68 ± 2.12                  41.01 ± 5.15                      0.007
  Alanine aminotransferase (IU/L)                        34.38 ± 14.35                 33.27 ± 23.16                     0.855
  Ascites (present/absent)                               1/31                          3/139                             0.560
  Types of hepatectomy (major/minor)                     24/8                          128/14                            0.020
  Hepatitis B virus Pre-S1 antigen (positive/negative)   20/12                         86/56                             0.839
  Antiviral therapy (yes/no)                             2/30                          64/78                             \< 0.001

BCLC, Barcelona Clinic Liver Cancer.

###### Multivariate analysis with logistic regression to identify factors related to perioperative HBV reactivation

  Variable                                 Hazard ratio   95% confidence interval   *P*
  ---------------------------------------- -------------- ------------------------- -------
  Liver cirrhosis (present)                5.804          0.888--37.945             0.066
  Albumin ≤ 35g/L                          0.452          0.045--4.569              0.501
  Minor hepatectomy (≤ 3 liver segments)   4.695          1.257--17.537             0.021
  Noantiviral therapy                      8.164          1.831--36.397             0.006

Effect of HBV reactivation on recovery of liver function {#s2_3}
--------------------------------------------------------

At 1 week after hepatectomy, the antiviral and non-antiviral groups showed similar liver function in terms of alanine aminotransferase, total bilirubin, albumin, and prothrombin time (all *P* \> 0.05; Figure [2](#F2){ref-type="fig"}). However, alanine aminotransferase was significantly lower and albumin significantly higher in the antiviral group than in the non-antiviral group at 1 month after hepatectomy, indicating better liver function (both *P* \< 0.05; Figure [2](#F2){ref-type="fig"}). Stratifying patients according to whether they experienced HBV reactivation or not revealed no significant differences in alanine aminotransferase, total bilirubin, albumin, or prothrombin time at 1 week after surgery. At 1 month after hepatectomy, however, liver function was better in patients without HBV reactivation than in those who experienced it (Figure [3](#F3){ref-type="fig"}).

![Comparison of liver function between patients with or without perioperative antiviral therapy](oncotarget-08-15047-g002){#F2}

![Comparison of liver function between patients who experienced post-hepatectomy HBV reactivation or not](oncotarget-08-15047-g003){#F3}

DISCUSSION {#s3}
==========

The major drug treatments against chronic HBV infection, interferon and nucleoside/nucleotide analogues, usually do not completely eliminate the virus \[[@R20]\]. Even with these treatments, some copies of HBV covalently closed circular DNA persist in infected hepatocytes \[[@R21]\]. As a result, immunosuppressive drug therapy and surgery can trigger genome amplification, leading in turn to HBV reactivation \[[@R19]\]. For patients with HBV-related HCC who are positive for HBV DNA, official guidelines recommend entecavir and tenofovir as first-line postoperative antiviral therapy to suppress viral replication and thereby help improve liver function, decrease tumor recurrence, and prolong overall survival \[[@R16]--[@R18]\]. The present study shows that perioperative antiviral therapy with entecavir can also improve prognosis of patients who are negative for HBV DNA.

To our knowledge, this is the first systematic study to explore the incidence of HBV reactivation after hepatectomy in HCC patients who are positive for serum HBsAg but negative for HBV DNA at baseline. Our results show a 9-fold reduction in the rate of HBV reactivation within 1 month of hepatectomy when antiviral therapy is begun a few days before surgery and continued for at least 1 month afterwards.

Our results indicate that HBV reactivation is a serious concern even for HCC patients who are negative for viral DNA at baseline. This extends and complements an already extensive literature documenting the substantial risk of reactivation in patients positive for viral DNA. In one study of 55 HCC patients with high levels of HBV DNA (≥ 7 mEq/ml) at baseline, post-hepatectomy reactivation occurred in 28% and hepatitis in 24% \[[@R22]\]. Another study of HCC patients with high HBV DNA levels (≥ 2.0 × 10^3^ IU/ml) reported rates of HBV reactivation during the perioperative period of 31.8% (14/44) in the non-antiviral group and 2.5% (1/40) in the antiviral group \[[@R23]\]. HBV reactivation rates also appear to be relatively high for patients with lower levels of viral DNA. In a study of HCC patients with preoperative HBV DNA levels \< 2.0 × 10^2^ IU/ml, reactivation occurred after hepatectomy in 21.1% without antiviral therapy \[[@R7]\]. In a study of patients with preoperative HBV DNA \< 2000 IU/ml, reactivation occurred after resection in 19.1% \[[@R12]\]. This last study identified HBV DNA levels \> 200 IU/ml and HBV reactivation as independent risk factors of poor disease-free and overall survival. The present results with HBV DNA-negative HCC patients, together with the existing literature on DNA-positive patients, strongly suggest that all HBsAg-positive HCC patients face substantial risk of postoperative reactivation. Thus, it may be beneficial to routinely administer prophylactic antiviral treatment to such patients before and immediately after hepatectomy.

How HBV reactivation occurs remains unclear. Hepatectomy may induce immunosuppression and thereby lead to HBV replication \[[@R24]--[@R26]\]. Subsequent recovery of immune function results in rapid destruction of infected hepatocytes, causing postoperative hepatitis and acute hepatic failure. In addition, HBV can integrate into liver cells and persist for long periods, protected from immune monitoring. As liver cells regenerate following hepatectomy, HBV can infect these cells because of its strong hepatotropism, causing viral load to increase.

In our cohort, minor hepatectomy was a risk factor of HBV reactivation. How this procedure can reactivate viral replication is poorly understood. We attribute this association to the issue of residual viral load. Major hepatectomy, in theory, eliminates a large amount of HBV load, and reactivation in the remnant liver should be difficult to detect since relatively little hepatic tissue remains and the cells regenerate slowly. In minor hepatectomy, however, remnant liver volume is large and so is the residual viral load. The residual liver tissue can regenerate fairly quickly, and the abundant HBV can infect the new tissue relatively easily. Thus, it stands to reason that minor hepatectomy leads to greater risk of postoperative HBV reactivation than the corresponding major procedure. We did not observe that liver cirrhosis, albumin ≤ 35 g/L or other clinical factors correlated significantly with HBV reactivation after hepatectomy.

Our results suggest that although the use of prophylactic antiviral therapy and occurrence of HBV reactivation do not appear to significantly improve liver function within 1 week after hepatectomy, they can influence function at 1 month. This may reflect the fact that liver function soon after hepatectomy reflects primarily damage due to the surgery itself, whereas damage over longer periods reflects the continuous processes that give rise to reactivation. Our results are consistent with previous reports that antiviral therapy can reduce HBV reactivation-induced liver damage, improve liver function, promote hepatocyte regeneration and increase the volume of residual liver after hepatectomy \[[@R27]--[@R29]\]. Since our study focused on the perioperative period, we did not conduct longer follow-up. Future studies should be repeated with longer follow-up to examine the prognosis of HBV DNA-negative patients with HBV-related HCC who receive prophylactic antiviral therapy.

In addition to its short follow-up, our study has several other limitations. During the first week, we did not assay liver function using the ascites test, even though this is one of the indices for Child-Pugh assessment of liver function. We did not use this test because the presence of ascites need not indicate poor liver function; it can also occur as a result of inflammation, lymphatic blockage, and changes in plasma osmotic pressure \[[@R30]\]. In addition, our study was based on a small sample, and our detection limit of 500 IU/ml of HBV DNA may not be sufficiently sensitive to detect low levels of viral replication. We did not genotype the HBV strains in our patients, leaving open the question of whether genotype influences risk of HBV reactivation. Last, patients were not randomized allocated. This study has the inherent defect of comparing management and surgery by different teams of surgeons, thus introducing possible biases into this study.

While our cohort contained only patients undergoing initial hepatectomy, HCC recurs in up to 75% of patients by 5 years after initial surgery \[[@R31]\]. Such patients must then undergo TACE, radiofrequency ablation, anhydrous alcohol injection, three-dimensional conformal radiotherapy, some other comprehensive multimodal treatment or even repeat surgery \[[@R32]--[@R33]\]. All these treatments can trigger HBV reactivation and further compromise liver function. Therefore our work demonstrating the clinical benefit of prophylactic antiviral therapy is likely to be relevant for patients with initial and recurrent HCC. In particular, our results support the use of perioperative antiviral therapy in HCC patients who are positive for HBsAg and negative for HBV DNA. Our results should be confirmed and extended in larger studies with longer follow-up.

MATERIALS AND METHODS {#s4}
=====================

Consent and ethical approval statement {#s4_1}
--------------------------------------

Written informed consent was obtained from the patients in this study prior to their undergoing hepatectomy. All procedures in this study were in accordance with the rules of the Research Ethics Committee of the Affiliated Tumor Hospital of Guangxi Medical University and with the 1964 Helsinki Declaration and its amendments.

Patients {#s4_2}
--------

This prospective study involved 174 consecutive patients with HBV-related HCC who underwent hepatectomy between July 2012 and June 2016 at the Affiliated Tumor Hospital of Guangxi Medical University. All patients were assayed for HBsAg and its antibody, hepatitis B e antigen and its antibody, antibody to HBV core antigen, HBV Pre-S1, antibody to hepatitis C virus, HBV DNA, serum alanine aminotransferase, serum albumin, prealbumin, total bilirubin, prothrombin time, and alpha-fetoprotein. Patients also underwent computed tomography of the liver one week before surgery. The trial is retrospectively registered (July 11, 2016) at [Clinicaltrials.gov](http://Clinicaltrials.gov) (NCT02829359).

Patients were included in the present study if they satisfied all the following inclusion criteria: (a) they underwent initial hepatectomy, (b) they were positive for serum HBsAg before surgery, (c) they were negative for serum HBV DNA (\< 500 IU/ml); (d) their serum alanine aminotransferase was within the normal range, (e) they had Child-Pugh A liver function, (f) their HCC was confirmed by histopathology, and (g) they received either entecavir antiviral therapy or no antiviral therapy before (not exceeding 7 days) and after hepatectomy.

Patients were excluded from this trial if they met any of the following criteria: (a) they received TACE or other anti-tumor treatments prior to hepatectomy; (b) they had previously received antiviral treatment within 12 months of entering the study; or (c) they had autoimmune disease, malignant tumors in other organs, or other severe disease.

Levels of HBV DNA in serum were quantified using real-time polymerase chain reaction coupled to a fluorescence assay in a commercial hepatitis detection kit (DaAn Gene, Guangzhou, China). The manufacturer-specified lower limit of quantification was 500 IU/ml. HBV reactivation was defined as a shift in HBV DNA levels from being undetectable at baseline to being detectable. Liver function was compared before and after hepatectomy using the indices alanine aminotransferase, total bilirubin, albumin, and prothrombin time.

Patient allocation and perioperative management {#s4_3}
-----------------------------------------------

Our two Hepatobiliary Surgery Departments are divided into several medical teams by the senior doctors. In three medical teams, patients who met the inclusion criteria would receive entecavir (0.5 mg/d; Zhengda Tianqing, Lianyungang, China) starting 3 days before hepatectomy and for at least 1 month afterwards. These patients were assigned as the antiviral group. In the other medical teams, patients did not receive any antiviral therapy and they would be assigned as the non-antiviral group. Patients in the non-antiviral group who experienced HBV reactivation were considered for entecavir therapy after enrollment in the study, as per standard practices \[[@R16]\]. None of the patients in our study received immunological therapy during the perioperative period (defined as during hepatectomy or up to 1 month afterwards).

Hepatectomy was performed as described \[[@R34]--[@R35]\]. Perioperative data were recorded about type of hepatectomy, blood loss volume, tumor size, tumor capsule, duration of porta hepatis clamping, and duration of surgery. Data were also recorded about transfusion of red cells and blood plasma and about infusion of human blood albumin during and after hepatectomy. Indications for transfusions and infusions were as described \[[@R36]--[@R37]\]. The duration of inflow blood occlusion was defined to be the duration of porta hepatis clamping. Major hepatectomy was defined as the resection of three or more Couinaud segments; minor hepactectomy, as the resection of fewer than three segments.

On postoperative days 1--7, all patients received drug therapy \[Magnesium Isoglycyrrhizinate for Injection, 150 mg/d, Zhengda Tianqing, Lianyungang, China; Ademetionine 1,4-Butanedisulfonate for Injection, 1000mg/d, Abbott S.P.A, Via Pontina Km 5204010 Campoverde (Aprilia) LT, Italy\] to protect liver function and lower transaminase levels. HBVDNA levels, liver function, and blood clotting function were assayed on days 1, 3, 5, 7, 9 and 30 after hepatectomy. Criteria for hospital discharge included stability of vital signs with no fever, ability to tolerate solid food without vomiting, absence of other postoperative complications, control of postoperative pain, and ability to function at home independently or with home care \[[@R38]\].

Statistical analysis {#s4_4}
--------------------

Continuous data were reported as mean and standard deviation and compared between patient groups using the independent-samples *t* test. Categorical data were reported as percentages and compared between patient groups using the chi-squared or Fisher\'s exact tests as appropriate. Multivariate analysis with logistic regression was used to identify risk factors of HBV reactivation. The threshold of significance was defined as two-tailed *P* \< 0.05. Data were analyzed using SPSS 17.0 (IBM, USA).

CONCLUSIONS {#s5}
===========

We provide evidence that liver resection can trigger HBV reactivation during the perioperative period in patients who have HBV-related HCC and who are negative for serum HBV DNA. Our results further suggest that the risk of reactivation is significantly lower when such patients are given perioperative prophylactic antiviral therapy. Reducing the risk of reactivation helps improve postoperative liver function. However, the long-term efficacy of entecavir for such patients was unknown. Besides, patient without liver cirrhosis was not analyzed specifically. Therefore, our conclusions remain highly preliminary and must be verified in much larger studies with longer follow-up that take into account these limitations.
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